These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

290 related items for PubMed ID: 27633081

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44. Long-Acting Neurotensin Synergizes With Liraglutide to Reverse Obesity Through a Melanocortin-Dependent Pathway.
    Ratner C, He Z, Grunddal KV, Skov LJ, Hartmann B, Zhang F, Feuchtinger A, Bjerregaard A, Christoffersen C, Tschöp MH, Finan B, DiMarchi RD, Leinninger GM, Williams KW, Clemmensen C, Holst B.
    Diabetes; 2019 Jun; 68(6):1329-1340. PubMed ID: 30936142
    [Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49. Contribution of brown adipose tissue activity to the control of energy balance by GLP-1 receptor signalling in mice.
    Heppner KM, Marks S, Holland J, Ottaway N, Smiley D, Dimarchi R, Perez-Tilve D.
    Diabetologia; 2015 Sep; 58(9):2124-32. PubMed ID: 26049402
    [Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. Early liraglutide treatment is better in glucose control, β-cell function improvement and mass preservation in db/db mice.
    Shao Y, Yuan G, Feng Y, Zhang J, Guo X.
    Peptides; 2014 Feb; 52():134-42. PubMed ID: 24406898
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
    Nauck MA, Meier JJ, Cavender MA, Abd El Aziz M, Drucker DJ.
    Circulation; 2017 Aug 29; 136(9):849-870. PubMed ID: 28847797
    [Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. Influence of Porphyromonas gingivalis in gut microbiota of streptozotocin-induced diabetic mice.
    Ohtsu A, Takeuchi Y, Katagiri S, Suda W, Maekawa S, Shiba T, Komazaki R, Udagawa S, Sasaki N, Hattori M, Izumi Y.
    Oral Dis; 2019 Apr 29; 25(3):868-880. PubMed ID: 30667148
    [Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. Place in therapy for liraglutide and saxagliptin for type 2 diabetes.
    McFarland MS, Brock M, Ryals C.
    South Med J; 2011 Jun 29; 104(6):426-39. PubMed ID: 21886033
    [Abstract] [Full Text] [Related]

  • 60. Long-Term Treatment with Liraglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, Has No Effect on β-Amyloid Plaque Load in Two Transgenic APP/PS1 Mouse Models of Alzheimer's Disease.
    Hansen HH, Fabricius K, Barkholt P, Kongsbak-Wismann P, Schlumberger C, Jelsing J, Terwel D, Termont A, Pyke C, Knudsen LB, Vrang N.
    PLoS One; 2016 Jun 29; 11(7):e0158205. PubMed ID: 27421117
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.